
    
      After up to 7-day screening period, Eligible Patients will be randomized to 1 of 3 treatment
      groups, and begin treatment with BTDS 5mg, 10mg,20mg for 7 days.Venous blood will be
      collected at 0, 6, 12, 24, 36, 48, 60, 72, 96,120, 144,168,169,170,171,172,174,180,192,216,
      240 h postdose respectively.Plasma concentrations of buprenorphine and norbuprenorphine will
      be analyzed to determine the following pharmacokinetic parameters: AUC0-t, AUC0-inf, Cmax,
      Tmax, tÂ½.
    
  